94 related articles for article (PubMed ID: 7606715)
1. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
Qin H; Chen W; Takahashi M; Disis ML; Byrd DR; McCahill L; Bertram KA; Fenton RG; Peace DJ; Cheever MA
Cancer Res; 1995 Jul; 55(14):2984-7. PubMed ID: 7606715
[TBL] [Abstract][Full Text] [Related]
2. [CD4+ T-cell immunity and Ab responses to mutant ras protein in pancreas and colon cancer patients].
Qin H; Chen W; Takahashi M
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):173-6. PubMed ID: 9387247
[TBL] [Abstract][Full Text] [Related]
3. Antibody to ras proteins in patients with colon cancer.
Takahashi M; Chen W; Byrd DR; Disis ML; Huseby ES; Qin H; McCahill L; Nelson H; Shimada H; Okuno K
Clin Cancer Res; 1995 Oct; 1(10):1071-7. PubMed ID: 9815896
[TBL] [Abstract][Full Text] [Related]
4. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides.
Yokomizo H; Matsushita S; Fujisao S; Murakami S; Fujita H; Shirouzu M; Yokoyama S; Ogawa M; Nishimura Y
Hum Immunol; 1997 Jan; 52(1):22-32. PubMed ID: 9021406
[TBL] [Abstract][Full Text] [Related]
7. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
Schott ME; Wells DT; Schlom J; Abrams SI
Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
[TBL] [Abstract][Full Text] [Related]
8. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
[TBL] [Abstract][Full Text] [Related]
9. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
10. Mutant ras epitopes as targets for cancer vaccines.
Abrams SI; Hand PH; Tsang KY; Schlom J
Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
[TBL] [Abstract][Full Text] [Related]
11. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
12. Identification of peptide superagonists for a self-K-ras-reactive CD4+ T cell clone using combinatorial peptide libraries and mass spectrometry.
Tanaka Y; Ohyama H; Ogawa M; Nishimura Y; Matsushita S
J Immunol; 1999 Jun; 162(12):7155-61. PubMed ID: 10358161
[TBL] [Abstract][Full Text] [Related]
13. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
14. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
15. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
16. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
17. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel oncogenic K-ras mutation in colon cancer.
Akagi K; Uchibori R; Yamaguchi K; Kurosawa K; Tanaka Y; Kozu T
Biochem Biophys Res Commun; 2007 Jan; 352(3):728-32. PubMed ID: 17150185
[TBL] [Abstract][Full Text] [Related]
19. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563
[TBL] [Abstract][Full Text] [Related]
20. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
Kanovsky M; Michl J; Botzolaki G; Morin J; Kovac C; Chung DL; Chie L; Friedman FK; Pincus MR
Cancer Chemother Pharmacol; 2003 Sep; 52(3):202-8. PubMed ID: 12783204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]